Founded in 2021 in Beijing E-Town, Byongen Therapeutics is an innovative biotech focused on original breakthroughs in AAV delivery. Our mission is to solve core delivery challenges through systematic capsid engineering, paving the way for safer and higher-performing gene therapies.
Our proprietary DynEvoLib® platform fuses AI and rational design with high-throughput directed evolution.Targeting muscular, CNS, and cardiovascular diseases, we are committed to optimizing delivery performance to provide patients with precise, effective, and clinically accessible gene medicines.
Overcoming delivery bottlenecks to unlock the full potential of gene therapy
We are dedicated to pioneering original innovation to develop precise, safe, and effective genetic medicines, addressing significant unmet clinical needs for patients worldwide.
To build an advanced AAV vector R&D and clinical translation platform.
By continuously iterating high-performance engineered capsids, we aim to improve the efficiency of novel vector development. Our goal is to accelerate the clinical translation of precision gene therapies for neuromuscular and central nervous system (CNS) diseases, providing patients with more clinically meaningful treatment options.
京公网安备11011502040057号
